Grifols (GIKLY) Total Current Liabilities (2010 - 2025)
Grifols (GIKLY) reported Total Current Liabilities of $2.4 billion for Q4 2025, up 2.01% on a YoY basis from $2.3 billion in Q4 2024, and up 2.01% quarter-over-quarter from $2.3 billion in Q4 2024.
Grifols (GIKLY) Total Current Liabilities (2010 - 2025) Analysis & Trends
Grifols has reported Total Current Liabilities for 16 years, with the latest figure at $2.4 billion in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities rose 2.01% year-over-year to $2.4 billion; the trailing twelve-month figure through Dec 2025 stood at $2.4 billion (up 2.01% YoY), and the FY2025 full-year result was $2.4 billion, up 4900.43% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $2.4 billion, up from $2.3 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $4.0 billion in Q4 2021, with the low at $2.1 billion in Q4 2022.
- Historically, Total Current Liabilities has averaged $2.6 billion across 5 years, with a median of $2.4 billion in 2025.
- Annual changes were most pronounced in 2021 — Total Current Liabilities surged 149.68% — and 2022, when it sank 48.17%.
- Grifols' Total Current Liabilities stood at $4.0 billion in 2021, then slumped by 48.17% to $2.1 billion in 2022, then climbed by 21.45% to $2.5 billion in 2023, then fell by 7.92% to $2.3 billion in 2024, then gained by 2.01% to $2.4 billion in 2025.
- The last three Total Current Liabilities figures came in at $2.4 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.5 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -30.24 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Grifols | - | - | - | 2.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.35 Bn |
| Dec 31, 2024 | 2.30 Bn |
| Dec 31, 2023 | 2.50 Bn |
| Dec 31, 2022 | 2.06 Bn |
| Dec 31, 2021 | 3.97 Bn |
| Dec 31, 2020 | 1.59 Bn |
| Sep 30, 2020 | 1.45 Bn |
| Mar 31, 2020 | 1.47 Bn |
| Dec 31, 2019 | 1.51 Bn |
| Sep 30, 2019 | 1.55 Bn |
| Dec 31, 2018 | 1.44 Bn |
| Sep 30, 2018 | 1.26 Bn |
| Jun 30, 2018 | 1.21 Bn |
| Mar 31, 2018 | 1.49 Bn |
| Dec 31, 2017 | 1.15 Bn |
| Jun 30, 2017 | 989.95 Mn |
| Dec 31, 2016 | 1.16 Bn |
| Sep 30, 2016 | 1.03 Bn |
| Jun 30, 2016 | 1.10 Bn |
| Dec 31, 2015 | 1.15 Bn |